API Quick Links: http://en.hichipharm.com/

+86-152-0110-8103 yanglm@beilupharma.com

EN

EN
jp
fr
de
es
ru
pt
ar

- English
- 日本語
- français
- Deutsch
- Español
- русский
- português
- العربية

Beilu Pharmaceutical Obtains GMP Certification from ANVISA

2024/11/01

Recently, Beijing Beilu Pharmaceutical Co., Ltd.'s contrast agent production linepassed the GMP (Good Manufacturing Practice) certification by Brazil's National Health Surveillance Agency (ANVISA).

Brazil is the largest country in South America. Beilu Pharmaceutical's successful passing of the Brazil's ANVISA GMP certification this time has created conditions for the company's contrast agent products to successfully enter the Brazilian market and has a very positive effect on the company further expanding the Brazilian market and other international markets.

In the first three quarters of 2024, Beilu Pharmaceutical's overseas market business progressed smoothly, with continuous growth in overseas revenue. While the pace of overseas registration for contrast agent products is accelerating, Hichi Pharmaceuticals' iodine APIs continue to expand in the overseas market, and gadolinium APIs produced by the Cangzhou subsidiary are also gradually achieving internationalization. At present, the company's products have been sold to 26 countries, with additional registrations ongoing in 30 other countries or regions. As the company successfully passes the ANVISA GMP certification, the competitiveness of its products in international markets will be further enhanced, and the pace of internationalization is expected to accelerate.

References

Related Products

Gadopentetate Dimeglumine

Gadopentetate Dimeglumine

Gadobutrol Injection/API

Gadobutrol Injection/API

Related News

Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!
February 18, 2022Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Follow...view
What is the Contrast Material? How Does It Work?
July 5, 2022Ⅰ. What is the contrast material?Contrastive material is used to improve the contrast of the images produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound, allo...view
Beilu Pharmaceutical Plans to Acquire Tianyuan Pharmaceutical, Actively Building "Second Growth Curve"
March 1, 2024Recently, Beilu Pharmaceutical announced that it plans to use its own funds to acquire 80% of the equity of Chengde Tianyuan Pharmaceutical Co., Ltd. After the completion of this acquisition, Tianyuan...view
Frequently Asked Questions about Iodine Contrast Users(1)
May 13, 20211. Can people at high risk of thyroid toxicity be injected with iodinated contrast agents?view
【New Product】Beilu Pharmaceutical's Gadoteric Acid Meglumine Injection and API Approved
July 11, 2024Recently, Beilu Pharmaceuticals received the Drug Registration Certificate for Gadopentetate Dimeglumine Injection and the approval notice for the marketing application of Gadopentetate Dimeglumine as...view
Congratulations: Beilu Pharma's Iodixanol Injection Passed the Consistency Evaluation for Generic Drugs
May 18, 2021Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA) on Iodixanol Injection.view

Call us on:
+86-152-0110-8103
Email Us:
yanglm@beilupharma.com
No.3 Shuiyuan West Road, Miyun District, Beijing, China

Sitemap | Privacy Policy
Copyright © Beijing Beilu Pharmaceutical Co., Ltd. All Rights Reserved.

+86-152-0110-8103